Anika Therapeutics, Inc. (ANIK)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$20.81-0.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · ANIK
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 120.7 | 112.8 | 119.9 | 120.8 | 113.8 | 147.8 | 130.5 | 114.6 | 105.6 | 113.4 | 103.4 | 93.0 | 105.6 | 75.1 | 71.4 | 64.8 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 113.4 | 103.4 | 93.0 | 105.6 | 75.1 | 71.4 | 64.8 |
| Cost of Revenues | 45.7 | 49.0 | 43.9 | 38.3 | 40.6 | 64.9 | 61.4 | 28.7 | 31.3 | — | — | — | — | — | — | — |
| Gross Profit | 75.0 | 63.8 | 76.0 | 82.5 | 73.2 | 82.9 | 69.0 | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 52.7 | 49.1 | 55.6 | 59.9 | 51.2 | 74.1 | 60.1 | 35.0 | 34.3 | 21.5 | 18.0 | 14.8 | 15.1 | 12.9 | 14.7 | 17.9 |
| R&D Expenses | 27.5 | 25.8 | 25.5 | 21.8 | 18.3 | 27.3 | 23.4 | 16.7 | 18.2 | 18.8 | 10.7 | 9.0 | 8.1 | 7.1 | 5.4 | 6.2 |
| Operating Income | (5.1) | (11.1) | (5.1) | 0.8 | 3.7 | 2.6 | (28.3) | 34.2 | 21.7 | 45.7 | 50.6 | 48.1 | 61.4 | 32.6 | 19.7 | 14.0 |
| Earnings from Continuing Operations | ||||||||||||||||
| EBT, Incl. Unusual Items | (2.9) | (9.3) | (2.8) | 3.2 | 4.3 | 2.4 | (28.6) | 36.1 | 23.2 | 46.2 | 50.9 | 48.3 | 61.5 | 32.5 | 19.5 | 13.8 |
| Income Tax Expense | 0.2 | 0.7 | 6.1 | 6.6 | 2.1 | (1.7) | (4.6) | 8.9 | 4.5 | 14.4 | 18.3 | 17.5 | 23.2 | 11.9 | 7.8 | 5.3 |
| Net Income | ||||||||||||||||
| Net Income | (3.9) | (10.9) | (56.4) | (83.0) | (15.0) | 4.0 | (24.0) | 27.2 | 18.7 | 31.8 | 32.5 | 30.8 | 38.3 | 20.6 | 11.8 | 8.5 |
| Per Share | ||||||||||||||||
| Basic EPS | (0.29) | (0.76) | (3.83) | (5.64) | (1.02) | 0.29 | (1.69) | 1.93 | 1.30 | 2.18 | 2.22 | 2.06 | 2.61 | 1.46 | 0.89 | 0.65 |
| Diluted EPS | (0.28) | (0.76) | (3.83) | (5.64) | (1.02) | 0.28 | (1.69) | 1.89 | 1.27 | 2.11 | 2.15 | 2.01 | 2.51 | 1.39 | 0.82 | 0.62 |
| Revenue per Share | 8.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 13.3 | 14.3 | 14.7 | 14.7 | 14.6 | 14.4 | 14.2 | 14.1 | 14.4 | 14.6 | 14.7 | 14.9 | 14.7 | 14.1 | 13.3 | 13.1 |
| Diluted Weighted Avg Shares | 13.7 | 14.3 | 14.7 | 14.7 | 14.8 | 14.6 | 14.2 | 14.4 | 14.7 | 15.1 | 15.1 | 15.3 | 15.3 | 14.8 | 14.3 | 13.7 |
| Supplemental | ||||||||||||||||
| EBITDA | — | (5.7) | 1.8 | 7.3 | 10.4 | 9.1 | (22.2) | 39.2 | 27.7 | 50.0 | 54.3 | 51.9 | 66.2 | 37.4 | 24.2 | 18.0 |
| EBIT | (5.1) | (11.1) | (5.1) | 0.8 | 3.7 | 2.6 | (28.3) | 34.2 | 21.7 | 45.7 | 50.6 | 48.1 | 61.4 | 32.6 | 19.7 | 14.0 |
| Effective Tax Rate | -7.1% | — | — | 209.0% | 49.1% | -70.3% | 16.2% | 24.7% | 19.3% | 31.1% | 36.0% | 36.3% | 37.7% | 36.7% | 39.8% | 38.6% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.